Surrozen, Inc.

Equities

SRZN

US86889P2083

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-02 EDT			5-day change	1st Jan Change
10.22 ^USD	-4.49%		+2.71%	+8.72%

06-10	Surrozen, Inc. Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver in Milan	CI
06-04	Surrozen Begins Dosing First Patient in Phase 1 Trial for Alcohol-Related Hepatitis Treatment	MT

Tranche Update on Surrozen, Inc.'s Equity Buyback Plan announced on December 15, 2022.

December 15, 2022 at 09:22 am

From December 12, 2022 to December 15, 2022, the company has repurchased 1,310,496 shares, for $2.7 million. With this, the company has completed the repurchase of 1,310,496 shares, for $2.7 million under the buyback announced on December 15, 2022.

Latest news about Surrozen, Inc.

Surrozen, Inc. Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver in Milan	06-10	CI
Surrozen Begins Dosing First Patient in Phase 1 Trial for Alcohol-Related Hepatitis Treatment	06-04	MT
Surrozen, Inc. Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis	06-04	CI
Surrozen, Inc. Presents Data Demonstrating the Promise of Antibody-Based Wntimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology Annual Meeting	05-09	CI
Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-10	CI
Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing	04-08	MT
Surrozen, Inc. announced that it has received $17.500008 million in funding from The Column Group, LLC, Ra Capital Management, Inc.	04-03	CI
Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis	04-01	CI
Surrozen, Inc. announced that it expects to receive $17.549999 million in funding	03-31	CI
Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer	02-07	CI
Sector Update: Health Care Stocks Softer Late Thursday Afternoon	01-18	MT
Sector Update: Health Care Stocks Weaker Thursday Afternoon	01-18	MT
Surrozen to Stop Inflammatory Bowel Disease Clinical Trial; Shares Fall	01-18	MT
Surrozen, Inc. Provides Corporate Update on Clinical Programs	01-18	CI
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis	11-08	CI
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Surrozen, Inc. Announces Management Changes	23-07-19	CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell Microcap Index	23-06-23	CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell Microcap Value Index	23-06-23	CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell 3000E Value Index	23-06-23	CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell 3000E Index	23-06-23	CI
Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Surrozen, Inc. Announces Appointment of Eric Bjerkholt to its Board	23-04-05	CI

Chart Surrozen, Inc.

Duration

Period

More charts

Company Profile

Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the bodyâs existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozenâs SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozenâs SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.22 USD

Average target price

33 USD

Spread / Average Target

+222.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SURROZEN, INC.	+8.72%	32.69M
MODERNA, INC.	+17.72%	44.87B
IQVIA HOLDINGS INC.	-10.33%	37.8B
LONZA GROUP AG	+42.32%	37.61B
ALNYLAM PHARMACEUTICALS, INC.	+29.36%	31.32B
CELLTRION, INC.	-8.44%	27.4B
ICON PUBLIC LIMITED COMPANY	+12.45%	26.32B
UNITED THERAPEUTICS CORPORATION	+44.19%	14.07B
MEDPACE HOLDINGS, INC.	+31.93%	12.5B
BIO-TECHNE CORPORATION	-7.67%	11.23B

Other Biotechnology & Medical Research